Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly significantly improved signs and…Original Article
FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
